

SUPPLEMENTARY MATERIAL

Table S1 Change from baseline to week 12 in key lipid parameters by week 12 apoA1 remnant ratio threshold and evolocumab dose/dose frequency

Change from baseline in parameter	Evolocumab dose/dose frequency					
	140 mg Q2W (<i>n</i> = 48)	420 mg QM (<i>n</i> = 53)	140 mg Q2W (<i>n</i> = 174)	420 mg QM (<i>n</i> = 177)	140 mg Q2W (<i>n</i> = 519)	420 mg QM (<i>n</i> = 518)
	Week 12 apoA1 remnant ratio threshold					
	< 3.6		3.6–6.0		> 6.0	
LDL-C (mg/dl), mean (SE)	-79.3 (4.4)	-67.5 (8.0)	-77.2 (2.8)	-70.1 (3.0)	-71.6 (1.3)	-70.6 (1.3)
<i>p</i> value ^a			0.0412			0.9454
HDL-C (mg/dl), mean (SE)	0.8 (1.1)	0.04 (1.5)	2.7 (0.6)	1.9 (0.5)	3.9 (0.4)	3.5 (0.3)
<i>p</i> value ^a			0.0152			0.0004
Non-HDL-C (mg/dl), mean (SE)	-89.1 (4.6)	-76.1 (8.4)	-84.7 (2.9)	-76.2 (3.2)	-77.0 (1.4)	-75.6 (1.3)
<i>p</i> value ^a			0.0033			0.6645

VLDL-C (mg/dl),	2.25	1.0	-3.0	-2	-3.0	-3.0
median (Q1, Q3)	(-10.0, 9.5)	(-12.0, 3.0)	(-9.0, 3.0)	(-8.0, 4.0)	(-7.0, 0.5)	(-7.0, 0.5)
<i>p</i> value^a			0.012		0.0413	
Lp(a) (nmol/l),	-11	-12	-9	-7	-10	-8
median (Q1, Q3)	(-24.0, -1.0)	(-28.0, -1.0)	(-25.0, -2.0)	(-21.0, 0.0)	(-25.0, -1.0)	(-26.0, -1.0)
<i>p</i> value^a		0.9879			0.4653	
ApoA1 (mg/dl),						
mean (SE)	9.2 (2.8)	6.2 (3.6)	10.0 (1.3)	6.8 (1.4)	8.7 (0.8)	8.5 (0.8)
<i>p</i> value^a		0.6156			0.5423	
ApoB (mg/dl),						
mean (SE)	-55.0 (2.6)	-46.2 (4.5)	-51.5 (1.7)	-45.4 (1.8)	-46.3 (0.9)	-44.7 (0.8)
<i>p</i> value^a		0.0004			0.5677	

n number of subjects in the full analysis set, *ApoA1* apolipoprotein A1, *ApoA1 remnant ratio* apoA1/(non-HDL-C - LDL-C), *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *Lp(a)* lipoprotein(a), *Q2W* every 2 weeks, *QM* monthly, *SE* standard error, *VLDL-C* very low-density lipoprotein cholesterol

^a*p* values are for 3-way comparison by dosing frequency group. Values < 0.05 are in bold text

No clear pattern in these results was identified by treatment group or achieved apoA1 remnant ratio